Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer

morphologic and molecular backgrounds and future promises

M. Santoni, M. Scarpelli, R. Mazzucchelli, A. Lopez-Beltran, Liang Cheng, S. Cascinu, R. Montironi

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Prostate-specific membrane antigen (PSMA) is an integral, non-shed membrane glycoprotein that is highly expressed on prostate epithelial cells and strongly upregulated in prostate cancer (PCa). Prostatic neoplastic transformation results in the transfer of PSMA from the apical membrane to the luminal surface of the ducts. However, the role of PSMA in tumor angiogenesis and carcinogenesis is poorly understood. PSMA is characterized by folate hydrolase and carboxypeptidase activity and internalization function, and its levels are directly correlated to androgen independence, metastasis and PCa progression. As largely substantiated by preclinical and clinical findings, PSMA could represent a promising target for Positron Emission Tomography (PET) radiopharmaceuticals for PCa imaging. Furthermore, PSMA could prove an important target for the development of new therapeutic approaches, including PSMA-based aptamers, peptides, antibody-drug conjugated therapy, as well as radiotherapy and immunotherapy. This review will summarize the role of PSMA in PCa development and progression and its potential role in the diagnosis and treatment of patients with initial and advanced PCa.

Original languageEnglish
Pages (from-to)555-563
Number of pages9
JournalJournal of Biological Regulators and Homeostatic Agents
Volume28
Issue number4
StatePublished - Oct 1 2014

Fingerprint

Prostatic Neoplasms
Therapeutics
Peptide Aptamers
Carboxypeptidases
Radiopharmaceuticals
human glutamate carboxypeptidase II
Membrane Glycoproteins
Hydrolases
Folic Acid
Positron-Emission Tomography
Immunotherapy
Androgens
Prostate
Carcinogenesis
Radiotherapy
Epithelial Cells
Neoplasm Metastasis
Drug Therapy
Membranes
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer : morphologic and molecular backgrounds and future promises. / Santoni, M.; Scarpelli, M.; Mazzucchelli, R.; Lopez-Beltran, A.; Cheng, Liang; Cascinu, S.; Montironi, R.

In: Journal of Biological Regulators and Homeostatic Agents, Vol. 28, No. 4, 01.10.2014, p. 555-563.

Research output: Contribution to journalArticle

@article{09d1e8f4c0664760ac8076ef4231e8a9,
title = "Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises",
abstract = "Prostate-specific membrane antigen (PSMA) is an integral, non-shed membrane glycoprotein that is highly expressed on prostate epithelial cells and strongly upregulated in prostate cancer (PCa). Prostatic neoplastic transformation results in the transfer of PSMA from the apical membrane to the luminal surface of the ducts. However, the role of PSMA in tumor angiogenesis and carcinogenesis is poorly understood. PSMA is characterized by folate hydrolase and carboxypeptidase activity and internalization function, and its levels are directly correlated to androgen independence, metastasis and PCa progression. As largely substantiated by preclinical and clinical findings, PSMA could represent a promising target for Positron Emission Tomography (PET) radiopharmaceuticals for PCa imaging. Furthermore, PSMA could prove an important target for the development of new therapeutic approaches, including PSMA-based aptamers, peptides, antibody-drug conjugated therapy, as well as radiotherapy and immunotherapy. This review will summarize the role of PSMA in PCa development and progression and its potential role in the diagnosis and treatment of patients with initial and advanced PCa.",
author = "M. Santoni and M. Scarpelli and R. Mazzucchelli and A. Lopez-Beltran and Liang Cheng and S. Cascinu and R. Montironi",
year = "2014",
month = "10",
day = "1",
language = "English",
volume = "28",
pages = "555--563",
journal = "Journal of Biological Regulators and Homeostatic Agents",
issn = "0393-974X",
publisher = "Biolife SAS",
number = "4",

}

TY - JOUR

T1 - Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer

T2 - morphologic and molecular backgrounds and future promises

AU - Santoni, M.

AU - Scarpelli, M.

AU - Mazzucchelli, R.

AU - Lopez-Beltran, A.

AU - Cheng, Liang

AU - Cascinu, S.

AU - Montironi, R.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Prostate-specific membrane antigen (PSMA) is an integral, non-shed membrane glycoprotein that is highly expressed on prostate epithelial cells and strongly upregulated in prostate cancer (PCa). Prostatic neoplastic transformation results in the transfer of PSMA from the apical membrane to the luminal surface of the ducts. However, the role of PSMA in tumor angiogenesis and carcinogenesis is poorly understood. PSMA is characterized by folate hydrolase and carboxypeptidase activity and internalization function, and its levels are directly correlated to androgen independence, metastasis and PCa progression. As largely substantiated by preclinical and clinical findings, PSMA could represent a promising target for Positron Emission Tomography (PET) radiopharmaceuticals for PCa imaging. Furthermore, PSMA could prove an important target for the development of new therapeutic approaches, including PSMA-based aptamers, peptides, antibody-drug conjugated therapy, as well as radiotherapy and immunotherapy. This review will summarize the role of PSMA in PCa development and progression and its potential role in the diagnosis and treatment of patients with initial and advanced PCa.

AB - Prostate-specific membrane antigen (PSMA) is an integral, non-shed membrane glycoprotein that is highly expressed on prostate epithelial cells and strongly upregulated in prostate cancer (PCa). Prostatic neoplastic transformation results in the transfer of PSMA from the apical membrane to the luminal surface of the ducts. However, the role of PSMA in tumor angiogenesis and carcinogenesis is poorly understood. PSMA is characterized by folate hydrolase and carboxypeptidase activity and internalization function, and its levels are directly correlated to androgen independence, metastasis and PCa progression. As largely substantiated by preclinical and clinical findings, PSMA could represent a promising target for Positron Emission Tomography (PET) radiopharmaceuticals for PCa imaging. Furthermore, PSMA could prove an important target for the development of new therapeutic approaches, including PSMA-based aptamers, peptides, antibody-drug conjugated therapy, as well as radiotherapy and immunotherapy. This review will summarize the role of PSMA in PCa development and progression and its potential role in the diagnosis and treatment of patients with initial and advanced PCa.

UR - http://www.scopus.com/inward/record.url?scp=84925300464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925300464&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 555

EP - 563

JO - Journal of Biological Regulators and Homeostatic Agents

JF - Journal of Biological Regulators and Homeostatic Agents

SN - 0393-974X

IS - 4

ER -